Immunic Inc (IMUX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$7.28-1.75%

Close 2026-10-26 · 1-day change

Investment OutlookAs of Oct 25, 2026

What could strengthen or challenge Immunic Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.803
Annual ending 2026-12-31
Revenue	—	12.5M
EPS	—	-3.595
Annual ending 2027-12-31
Revenue	—	12.5M
EPS	—	-2.373

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Raise up to $400M through private placement	A primary condition in Immunic Inc's published investment case. The stated target is raise $400 million by 2026-Q1.	Intact	capital raised falls significantly below $400 million by 2026-Q1	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 25, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize leadership with new CEO and board chair	New leadership may improve strategy and execution.	Intact	further CEO or key leadership departures before end of 2026	Qualitative: CEO & Chair in place; 1 director exit (orderly) New Chair appointed May 2026. Director Nash resigned Sept 2026 with board size reduction. No CEO or key officer departures reported. Context reviewed through Oct 23, 2026Last status assessment Oct 25, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management has appointed a new CEO, board chair, and board member with relevant industry and MS expertise to support clinical and commercial transition. Financials show ongoing investment in development consistent with leadership strengthening. The trajectory reflects active execution on leadership transitions. Delivery assessment Oct 25, 2026
Manage net loss per share to -$1.08 or better	The company targets a net loss per share of $1.08 in 2026.	Intact	net loss per share worsens beyond -1.08 USD in FY26	Diluted EPS: $-0.80 per share FY2026-Q2; GAAP. Published target: net loss per share >= -1.08 USD in FY26. Target period ends 2026-12-31; this observation covers 2026-Q2. Source published Aug 11, 2026-0.8 USD/share · source valueSource reportLast status assessment Oct 25, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 00bf7379-ee45-435d-94a0-a4d0c525049a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management guided to a net loss per share of $(1.08) for 2026. Actual diluted EPS was -1.08 in 2026-Q1 and improved to -0.8 in 2026-Q2, while net income remained negative and operating losses persisted. The trajectory shows limited progress with ongoing losses consistent with clinical-stage biotech operations. Delivery assessment Oct 25, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.37

$-3.55 → $-2.37 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.55	$12,500,000	7 / 6
2026-07-25	$-3.56	$11,111,110	8 / 9
2026-07-26	$-3.56	$11,111,110	8 / 9
2026-07-27	$-3.56	$11,111,110	8 / 9
2026-07-28	$-3.56	$11,111,110	8 / 9
2026-07-29	$-3.56	$11,111,110	8 / 9
2026-07-30	$-3.56	$11,111,110	8 / 9
2026-07-31	$-3.63	$10,000,000	9 / 10
2026-08-01	$-3.63	$12,500,000	8 / 7
2026-08-02	$-3.63	$10,000,000	9 / 10
2026-08-03	$-3.63	$10,000,000	9 / 10
2026-08-04	$-3.63	$10,000,000	9 / 10
2026-08-05	$-3.63	$12,500,000	8 / 7
2026-08-06	$-3.63	$10,000,000	9 / 10
2026-08-07	$-3.63	$12,500,000	8 / 7
2026-08-08	$-3.63	$12,500,000	8 / 7
2026-08-09	$-3.63	$10,000,000	9 / 10
2026-08-10	$-3.63	$12,500,000	8 / 7
2026-08-12	$-3.63	$12,500,000	8 / 7
2026-08-13	$-3.63	$12,500,000	8 / 7
2026-08-14	$-3.63	$12,500,000	8 / 7
2026-08-15	$-3.63	$12,500,000	8 / 7
2026-08-16	$-3.63	$12,500,000	8 / 7
2026-08-17	$-3.63	$12,500,000	8 / 7
2026-08-18	$-3.63	$12,500,000	8 / 7
2026-08-19	$-3.63	$12,500,000	8 / 7
2026-08-20	$-2.52	$11,111,111	9 / 7
2026-08-21	$-2.52	$11,111,111	9 / 7
2026-08-22	$-2.39	$12,500,000	9 / 7
2026-08-23	$-2.39	$12,500,000	9 / 7
2026-08-24	$-2.39	$12,500,000	9 / 7
2026-08-25	$-2.39	$12,500,000	9 / 7
2026-08-26	$-2.39	$12,500,000	9 / 7
2026-08-27	$-2.39	$12,500,000	9 / 7
2026-08-28	$-2.39	$12,500,000	9 / 7
2026-08-29	$-2.39	$12,500,000	9 / 7
2026-08-30	$-2.39	$12,500,000	9 / 7
2026-08-31	$-2.39	$12,500,000	9 / 7
2026-09-01	$-2.39	$12,500,000	9 / 7
2026-09-02	$-2.39	$12,500,000	9 / 7
2026-09-03	$-2.44	$12,500,000	9 / 7
2026-09-04	$-2.44	$12,500,000	9 / 7
2026-09-05	$-2.44	$12,500,000	9 / 7
2026-09-06	$-2.44	$12,500,000	9 / 7
2026-09-07	$-2.44	$12,500,000	9 / 7
2026-09-08	$-2.44	$12,500,000	9 / 7
2026-09-09	$-2.44	$12,500,000	9 / 7
2026-09-10	$-2.44	$12,500,000	9 / 7
2026-09-11	$-2.43	$12,500,000	9 / 7
2026-09-12	$-2.43	$12,500,000	9 / 7
2026-09-13	$-2.43	$12,500,000	9 / 7
2026-09-14	$-2.43	$12,500,000	9 / 7
2026-09-15	$-2.43	$12,500,000	9 / 7
2026-09-16	$-2.43	$12,500,000	9 / 7
2026-09-17	$-2.43	$12,500,000	9 / 7
2026-09-18	$-2.43	$12,500,000	9 / 7
2026-09-19	$-2.43	$12,500,000	9 / 7
2026-09-20	$-2.43	$12,500,000	9 / 7
2026-09-21	$-2.43	$12,500,000	9 / 7
2026-09-22	$-2.43	$12,500,000	9 / 7
2026-09-23	$-2.43	$12,500,000	9 / 7
2026-09-24	$-2.43	$12,500,000	9 / 7
2026-09-25	$-2.43	$12,500,000	9 / 7
2026-09-26	$-2.43	$12,500,000	9 / 7
2026-09-27	$-2.43	$12,500,000	9 / 7
2026-09-28	$-2.43	$12,500,000	9 / 7
2026-09-29	$-2.43	$12,500,000	9 / 7
2026-09-30	$-2.43	$12,500,000	9 / 7
2026-10-01	$-2.43	$12,500,000	9 / 7
2026-10-02	$-2.43	$12,500,000	9 / 7
2026-10-03	$-2.43	$12,500,000	9 / 7
2026-10-04	$-2.43	$12,500,000	9 / 7
2026-10-05	$-2.43	$12,500,000	9 / 7
2026-10-06	$-2.43	$12,500,000	9 / 7
2026-10-07	$-2.43	$12,500,000	9 / 7
2026-10-08	$-2.43	$12,500,000	9 / 7
2026-10-09	$-2.43	$12,500,000	9 / 7
2026-10-10	$-2.43	$12,500,000	9 / 7
2026-10-11	$-2.43	$12,500,000	9 / 7
2026-10-12	$-2.43	$12,500,000	9 / 7
2026-10-13	$-2.43	$12,500,000	9 / 7
2026-10-14	$-2.43	$12,500,000	9 / 7
2026-10-15	$-2.43	$12,500,000	9 / 7
2026-10-16	$-2.43	$12,500,000	9 / 7
2026-10-17	$-2.43	$12,500,000	9 / 7
2026-10-18	$-2.43	$12,500,000	9 / 7
2026-10-19	$-2.43	$12,500,000	9 / 7
2026-10-20	$-2.43	$12,500,000	9 / 7
2026-10-21	$-2.43	$12,500,000	9 / 7
2026-10-22	$-2.43	$12,500,000	9 / 7
2026-10-23	$-2.43	$12,500,000	9 / 7
2026-10-24	$-2.43	$12,500,000	9 / 7
2026-10-25	$-2.37	$12,500,000	9 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	0	0
2026-06-01	10	0	0
2026-07-01	11	0	0
2026-08-01	12	0	0
2026-09-01	12	0	0
2026-10-01	13	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 26–Oct 25 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 26, 2026–Oct 25, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Raise up to $400M through private placementDirect metric needs a verified mapping
Manage net loss per share to -$1.08 or betterDiluted EPS: $-0.80 per share

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-60.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Immunic Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not a proven earnings compounder. The long-term thesis is in a watch state: management is focused on trial milestones and new leadership, while recent financial performance remains weak and confidence in the overall evidence is low.

What's priced into Immunic Inc

The evidence snapshot does not provide a valuation level or clear expectations already reflected in the market, so whether IMUX is cheap or expensive versus peers cannot be assessed. It reports low fragility, meaning no listed signals point to concentrated fragility, but that does not resolve the valuation gap.

What the fundamentals likely do

Near term, continued losses and negative operating cash flow point to ongoing funding needs, while management is pursuing a private placement of up to $400 million. The main multi-year fundamental driver is vidofludimus calcium, with Phase 3 results expected by year-end 2026 and a Phase 3 program planned in progressive MS; execution and leadership progress are mixed. A guidance cut is a stated risk, and the next results merit attention given the elevated risk and weak recent performance.

What Immunic Inc hinges on

The thesis hinges on clinical progress, including the expected late-2026 trial data, and on whether the company can fund development. A guidance cut would weaken the near-term setup, while continued strength among named Healthcare bellwethers could support sector momentum. Those sector signals are secondary to IMUX’s own clinical and funding execution over the multi-year view.